Drug Profile
Research programme: cellular and protein based therapeutics - Celyad Oncology
Alternative Names: C3BS GQR 4; C3BS-GQR-1; C3BS-GQR-2; C3BS-GQR-3; C3BS-PQR-1Latest Information Update: 15 Jun 2020
Price :
$50
*
At a glance
- Originator Cardio3 BioSciences
- Developer Celyad Oncology
- Class Proteins; Stem cell therapies
- Mechanism of Action Cell differentiation stimulants; Cell replacements; Stem cell stimulants; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Congenital heart defects; Heart failure; Myocardial infarction
Most Recent Events
- 10 Jun 2020 Celyad is now called Celyad Oncology
- 28 Nov 2018 No recent reports of development identified for preclinical development in Myocardial-infarction in Belgium
- 28 Nov 2018 No recent reports of development identified for research development in Congenital-heart-defects in Belgium